Clinical Trials on γδ T Cells in Japan

Total 911 results

SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Japan
Bristol-Myers Squibb

Completed

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Multiple Myeloma

Japan
Juntendo University
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Non-squamous Non-small-cell Lung Cancer | EGFR Activating Mutation

Japan
Genzyme, a Sanofi Company

Completed

A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell

Japan
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-3475A (Pembrolizumab Formulated With MK-5180) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Squamous Cell Carcinoma

Japan
University of the Ryukyus

Completed

Dose-finding Study of Colchicine in Type 2 Diabetic Patients With Coronary Artery Disease (DRC-04)

Coronary Artery Disease | Inflammation | Diabetes Mellitus, Type 2 | Diarrhea | Colchicine | White Blood Cell

Japan
Eli Lilly and Company

Completed

A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients

Non Small Cell Lung Cancer

Japan
Eli Lilly and Company

Completed

A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic

Japan
Eli Lilly and Company

Completed

To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

Japan
Spectrum Pharmaceuticals, Inc

Terminated

Study of Poziotinib in Japanese Patients With NSCLC

NSCLC

Japan
SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Low-grade B Cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated

Japan
Pfizer

Terminated

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Gastric Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Gastroesophageal Junction Cancer | Urothelial Cancer | Head and Neck Squamous Cell Carcinomas

United States, Japan
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Neuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)

Germany, Belgium, Japan, France
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase

Familial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic Syndromes

Japan
Boehringer Ingelheim

Terminated

BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
Merck Sharp & Dohme LLC

Completed

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Non-Small-Cell Lung Carcinoma

Japan
Pfizer

No longer available

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Neoplasms | Carcinoma, Non-Small-Cell Lung

Japan
AbbVie

Completed

A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

Small Cell Lung Cancer

Japan
Genzyme, a Sanofi Company

Completed

A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukemia

Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Hutchmed

Active, not recruiting

Open-label Study of Surufatinib in Japanese Patients

Neuroendocrine Tumors | Non-hematologic Malignancy

Japan
Novartis Pharmaceuticals

Terminated

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)

Carcinoma, Non-Small-Cell Lung

Japan, Korea, Republic of, Singapore
Genmab
AbbVie

Active, not recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL (EPCORE™ NHL-3)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

Japan
AstraZeneca

Completed

IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

Carcinoma, Small Cell

Japan
Duke University

Active, not recruiting

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma

United States, Japan, Italy, Korea, Republic of, Czechia, Singapore
SymBio Pharmaceuticals

Completed

Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

Diffuse Large B Cell Lymphoma

Japan
Bristol-Myers Squibb
AbbVie

No longer available

Early Patient Access Treatment Use Protocol CA204-220

Multiple Myeloma

Japan
Stanford University

Completed

Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)

Non-small Cell Lung Cancer (NSCLC)

United States, Japan, Canada
Japan Multinational Trial Organization

Completed

Irinotecan and Carboplatin in Treating Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

Lung Cancer

Japan
SymBio Pharmaceuticals

Completed

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
Astellas Pharma Inc
Seagen Inc.

Completed

A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Metastatic Urothelial Cancer

Japan
AstraZeneca

Active, not recruiting

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)

Carcinoma, Non-Small-Cell Lung | Small Cell Lung Carcinoma | Carcinoma, Squamous Cell of Head and Neck

United States, Taiwan, Korea, Republic of, Japan, Spain
Genzyme, a Sanofi Company

Completed

Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma

Multiple Myeloma

Japan
BeiGene

Active, not recruiting

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Japan
Novartis Pharmaceuticals

Recruiting

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

B-cell Non-Hodgkin Lymphoma (B-NHL) | B-cell Acute Lymphoblastic Leukemia (B-ALL)

Japan, Italy, Spain, Belgium, Singapore, France, United States, Israel
Eli Lilly and Company

Completed

A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Squamous Non-small Cell Lung Cancer

Japan
Taiho Pharmaceutical Co., Ltd.

Recruiting

AB122 Platform Study

Gastric Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Alveolar Soft Part Sarcoma | Advanced or Metastatic Solid Tumor

Japan
University of Toyama

Unknown

Study of Tissue Samples in Predicting How Well Chemotherapy and Radiation Therapy Will Kill Cancer Cells in Patients With Squamous Cell Carcinoma of the Esophagus

Esophageal Cancer

Japan
Takeda

Completed

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

Japan
University of Toyama

Unknown

Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer (RNCLC)

Small Cell Lung Cancer

Japan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma (MM)

Japan
Genzyme, a Sanofi Company

Completed

Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma

Japan
Osaka University
Merck Sharp & Dohme LLC; ISHIHARA SANGYO KAISHA,LTD. Japan

Unknown

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

Advanced Melanoma

Japan
Incyte Biosciences Japan GK

Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (J-MIND)

Diffuse Large B-cell Lymphoma | Non Hodgkins Lymphoma

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas

Glioblastoma | Diffuse Intrinsic Pontine Glioma

Japan
Pfizer

Completed

Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

Korea, Republic of, Japan, China
Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

WHO Grade II Glioma

Japan
Novartis Pharmaceuticals

Completed

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Non-Small-Cell Lung Cancer

Japan
SymBio Pharmaceuticals

Completed

Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

Lymphoma, B-cell, Diffuse

Japan
Pfizer

Recruiting

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

Melanoma | Neoplasms | Renal Cell Carcinoma | Non-small-cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Urothelial Carcinoma | Colorectal Carcinoma | Ovarian Carcinoma

United States, Japan, Puerto Rico

3

Subscribe